14158 Results (Page 41 of 567)
All Market Research Reports
US Clinical Nutrition for Cancer Care Market Analysis
The US Clinical Nutrition for Cancer Care Market was valued at $2,364.6 Mn in 2023 and is predicted to grow at a CAGR of 3.04 % from 2023 to 2030, to $2,916.07 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the US Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer, and Fresenius Kabi, among others.
Canada Clinical Nutrition for Cancer Care Market Analysis
The Canada Clinical Nutrition for Cancer Care Market was valued at $450.4 Mn in 2023 and is predicted to grow at a CAGR of 5.04% from 2023 to 2030, to $635.5 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the Canada Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer, and Fresenius Kabi, among others.
South Africa Gram-Negative Infection Therapeutics Market Analysis
The South Africa Gram-Negative Infection Therapeutics Market was valued at $96.7 Mn in 2023 and is predicted to grow at a CAGR of 7.13% from 2023 to 2030 to $156.6 Mn by 2030. Factors driving this growth encompass the high prevalence of multidrug-resistant (MDR) infections, rising awareness, and the expanding population with aging demographics. Leading companies in this market comprise Sanofi-Aventis, Eli Lilly and Company, and other notable entities.
Kenya Gram-Negative Infection Therapeutics Market Analysis
The Kenya Gram-Negative Infection Therapeutics Market was valued at $10.4 Mn in 2023 and is predicted to grow at a CAGR of 7% from 2023 to 2030 to $16.7 Mn by 2030. This growth is driven by rising antibiotic resistance, a high prevalence of multidrug-resistant (MDR) infections, and increasing awareness. Leading companies in this market include Baxter and AbbVie Inc., among others.
Egypt Gram-Negative Infection Therapeutics Market Analysis
The Egypt Gram-Negative Infection Therapeutics Market was valued at $41.6 Mn in 2023 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030 to $68.7 Mn by 2030. The primary drivers of this market expansion encompass the growing incidence of gram-negative bacterial infections, the challenge of antimicrobial resistance, and collaborative efforts through partnerships. Major players in this sector in Egypt include Janssen Pharmaceuticals, Inc. and Bristol-Myers Squibb Company, among others.
Vietnam Gram-Negative Infection Therapeutics Market Analysis
The Vietnam Gram-Negative Infection Therapeutics Market was valued at $74.4 Mn in 2023 and is predicted to grow at a CAGR of 6.13% from 2023 to 2030 to $112.8 Mn by 2030. This growth is fuelled by factors such as the increasing prevalence of antibiotic resistance, elevated rates of colonization with resistant strains, and rising mortality rates. Key players in this market include Merck, Takeda, Novartis, and other notable companies.
Singapore Gram-Negative Infection Therapeutics Market Analysis
The Singapore Gram-Negative Infection Therapeutics Market was valued at $17.8 Mn in 2023 and is predicted to grow at a CAGR of 6.5% from 2023 to 2030 to $27.7 Mn by 2030. Factors driving this expansion include increasing prevalence, rising demand for effective treatments, and an aging population. Major companies in this market include Novartis, Merck, Roche, and others.
Philippines Gram-Negative Infection Therapeutics Market Analysis
The Philippines Gram-Negative Infection Therapeutics Market was valued at $32.7 Mn in 2023 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030 to $50.5 Mn by 2030. Factors fuelling this expansion include rising prevalence, growing awareness of antibiotic resistance, and government initiatives. Key players in this market include AbbVie Inc., Bayer AG, and other significant firms.
Malaysia Gram-Negative Infection Therapeutics Market Analysis
The Malaysia Gram-Negative Infection Therapeutics Market was valued at $23.9 Mn in 2023 and is predicted to grow at a CAGR of 6.1% from 2023 to 2030 to $36.2 Mn by 2030. Key drivers of this growth include increasing antimicrobial resistance (AMR), an aging population, and government initiatives. Major companies in this market include Sumitomo, Baxter, and other prominent firms.
Japan Gram-Negative Infection Therapeutics Market Analysis
The Japan Gram-Negative Infection Therapeutics Market was valued at $924.6 Mn in 2023 and is predicted to grow at a CAGR of 6.4% from 2023 to 2030 to $1427.4 Mn by 2030. The primary factors fueling this market growth include the increasing challenge of antimicrobial resistance (AMR), the aging demographics, and government efforts. Major players in Japan's market include Eli Lilly and Company and Bayer AG, among others.
Indonesia Gram-Negative Infection Therapeutics Market Analysis
The Indonesia Gram-Negative Infection Therapeutics Market was valued at $89.2 Mn in 2023 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030 to $133.3 Mn by 2030. The main factors driving this market expansion include the rising prevalence of hospital-acquired infections (HAIs), increased demand due to the widespread overuse and misuse of antibiotics, and a fragmented healthcare system. Leading companies in this market in Indonesia include Kalbe Farma and Bio Farma, among others.
China Gram-Negative Infection Therapeutics Market Analysis
The China Gram-Negative Infection Therapeutics Market was valued at $1195.84 Mn in 2023 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030 to $1970.9 Mn by 2030. The key drivers of this market expansion include public health initiatives, the rising incidence of gram-negative infections, and the growing demand for effective treatments. The leading companies operating in this market in China include Merck & Co., Inc. and AstraZeneca, among others.
UK Gram-Negative Infection Therapeutics Market Analysis
The UK Gram-Negative Infection Therapeutics Market was valued at $386.8 Mn in 2023 and is predicted to grow at a CAGR of 3.9% from 2023 to 2030 to $505.5 Mn by 2030. Public health initiatives, rising incidence of infections, and a growing demand for effective treatments drive this market expansion. Leading companies in this market include GlaxoSmithKline plc (GSK), Pfizer Inc., Novartis, Takeda, and Baxter, among others.
Spain Gram-Negative Infection Therapeutics Market Analysis
The Spain Gram-Negative Infection Therapeutics Market was valued at $287.1 Mn in 2023 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030 to $401.3 Mn by 2030. Factors fuelling this market expansion include the aging population, heightened research and development efforts, and the increasing prevalence of gram-negative infections. Leading companies in this market include Sanofi, Novartis, Baxter, Takeda, and others.
Germany Gram-Negative Infection Therapeutics Market Analysis
The Germany Gram-Negative Infection Therapeutics Market was valued at $544.4 Mn in 2023 and is predicted to grow at a CAGR of 4.1% from 2023 to 2030 to $721.3 Mn by 2030. Key market growth drivers include increasing prevalence, technological advancements, and growing awareness of antimicrobial resistance (AMR). Major players in this market include Pfizer Inc., Nektar Therapeutics, and other notable companies.
France Gram-Negative Infection Therapeutics Market Analysis
The France Gram-Negative Infection Therapeutics Market was valued at $409.1 Mn in 2023 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030 to $571.8 Mn by 2030. This growth is fuelled by the rising prevalence of healthcare-associated infections (HAIs), affecting approximately 750,000 patients yearly, with a notable portion attributed to gram-negative bacteria. Key players in this market include Pfizer, Sanofi, Baxter, Takeda and others.
Mexico Gram-Negative Infection Therapeutics Market Analysis
The Mexico Gram-Negative Infection Therapeutics Market was valued at $223.1 Mn in 2023 and is predicted to grow at a CAGR of 6.15% from 2023 to 2030 to $338.8 Mn by 2030. This growth is driven by increasing prevalence, growing awareness, and rising investment in R&D. Major players in this market include Baxter and GlaxoSmithKline plc (GSK), among others.
Brazil Gram-Negative Infection Therapeutics Market Analysis
The Brazil Gram-Negative Infection Therapeutics Market was valued at $371.9 Mn in 2023 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030 to $593.29 Mn by 2030. Key market growth drivers include the increasing prevalence of gram-negative infections, rising antibiotic resistance, and technological advancements. Major players in this market include Nektar Therapeutics, Novartis, and other notable companies.
UAE Gram-Negative Infection Therapeutics Market Analysis
The UAE Gram-Negative Infection Therapeutics Market was valued at $74.4 Mn in 2023 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030 to $118.7 Mn by 2030. This growth is driven by increasing prevalence, with a rate of approximately 9.8% in healthcare settings. Major players in this market include AbbVie Inc. and Bayer AG, among others.
Saudi Arabia Gram-Negative Infection Therapeutics Market Analysis
The Saudi Arabia Gram-Negative Infection Therapeutics Market was valued at $0.25 Bn in 2023 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030 to $0.42 Bn by 2030. Factors driving this market growth include increasing prevalence, the threat of nosocomial pneumonia, and an aging population. Prominent companies in this market include Baxter, Novartis, and others.
US Gram-Negative Infection Therapeutics Market Analysis
The US Gram-Negative Infection Therapeutics Market was valued at $6247.5 Mn in 2023 and is predicted to grow at a CAGR of 3.9% from 2023 to 2030 to $8166.1 Mn by 2030. A key factor driving this market growth is decreasing antibiotic resistance trends in gram-negative bacteria, increasing prevalence, and innovative therapeutics. Leading companies in this market include Pfizer Inc. and AbbVie Inc. (Allergan Pharmaceuticals Private Limited), among others.
Canada Gram-Negative Infection Therapeutics Market Analysis
The Canada Gram-Negative Infection Therapeutics Market was valued at $1190.08 Mn in 2023 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030 to $1777.5 Mn by 2030. Market dynamics are driven by the increasing incidence of infections, unmet medical needs, and favourable government initiatives. Leading companies in this market include AstraZeneca and Johnson & Johnson, among others.
India Home Infusion Therapy Market
The India Home Infusion Therapy Market was valued at $654 Mn in 2023 and is predicted to grow at a CAGR of 11.1% from 2023 to 2030, to $1366.3 Mn by 2030. The key drivers of the market include low cost, rising prevalence of chronic diseases, and expanding geriatric population. The prominent players of the India Home Infusion Therapy Market are Poly Medicure, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.
South Africa Home Infusion Therapy Market
The South Africa Home Infusion Therapy Market was valued at $233.7 Mn in 2023 and is predicted to grow at a CAGR of 9.33% from 2023 to 2030, to $436.4 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the South Africa Home Infusion Therapy Market are SA Homecare, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.
Kenya Home Infusion Therapy Market
The Kenya Home Infusion Therapy Market was valued at $25.2 Mn in 2023 and is predicted to grow at a CAGR of 9.2% from 2023 to 2030, to $46.6 Mn by 2030. The key drivers of the market include the rising prevalence of chronic diseases, the expanding geriatric population, and technological advancements. The prominent players of the Kenya Home Infusion Therapy Market are Poly Medicure, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.
